共 88 条
[11]
Planchard D(2020)A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs. nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS ≥1% metastatic NSCLC Cancers (Basel) 12 3648-51
[12]
Popat S(2020)Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration Nat Med 26 47-S985
[13]
Kerr K(2021)Abstract CT158: ctDNA analysis in the savolitinib phase II study in non-small cell lung cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14) Cancer Res 81 CT158-9020
[14]
Dong Y(2021)P45.03 Tepotinib in patients with MET exon 14 skipping NSCLC as identified by liquid or tissue biopsy J Thorac Oncol 16 S1085-4108
[15]
Xu J(2021)1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC Ann Oncol 32 S984-292
[16]
Sun B(2012)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves BMC Med Res Methodol 12 9-549
[17]
Wang J(2021)Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study J Clin Oncol 39 9020-663
[18]
Wang Z(2018)Pulmonary sarcomatoid carcinoma: University of Cincinnati experience Oncotarget 9 4102-68
[19]
Signorovitch JE(2017)Pulmonary sarcomatoid carcinoma: an analysis of the national cancer data base Clin Lung Cancer 18 286-10
[20]
Sikirica V(2015)Simulation and matching-based approaches for indirect comparison of treatments Pharmacoeconomics 33 537-16